Acknowledgement
This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean government (NRF-2019R1A5A2027340, 2021R1F1A1049941, and 2019R1A2C2084716 to E.J.C. and 2012R1A3A2048767 to H.D.Y.).
References
- Agarwal, S.K., Guru, S.C., Heppner, C., Erdos, M.R., Collins, R.M., Park, S.Y., Saggar, S., Chandrasekharappa, S.C., Collins, F.S., Spiegel, A.M., et al. (1999). Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96, 143-152. https://doi.org/10.1016/S0092-8674(00)80967-8
- Alimirah, F., Chen, J.M., Basrawala, Z., Xin, H., and Choubey, D. (2006). DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 580, 2294-2300. https://doi.org/10.1016/j.febslet.2006.03.041
- Balogh, K., Racz, K., Patocs, A., and Hunyady, L. (2006). Menin and its interacting proteins: elucidation of menin function. Trends Endocrinol. Metab. 17, 357-364. https://doi.org/10.1016/j.tem.2006.09.004
- Beltran, H., Tomlins, S., Aparicio, A., Arora, V., Rickman, D., Ayala, G., Huang, J.T., True, L., Gleave, M.E., Soule, H., et al. (2014). Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 20, 2846-2850. https://doi.org/10.1158/1078-0432.CCR-13-3309
- Chandrasekharappa, S.C., Guru, S.C., Manickam, P., Olufemi, S.E., Collins, F.S., EmmertBuck, M.R., Debelenko, L.V., Zhuang, Z.P., Lubensky, I.A., Liotta, L.A., et al. (1997). Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276, 404-407. https://doi.org/10.1126/science.276.5311.404
- Chou, C.W., Tan, X., Hung, C.N., Lieberman, B., Chen, M.Z., Kusi, M., Mitsuya, K., Lin, C.L., Morita, M., Liu, Z.J., et al. (2020). Menin and meninassociated proteins coregulate cancer energy metabolism. Cancers (Basel) 12, 2715. https://doi.org/10.3390/cancers12092715
- Chu, K., Cheng, C.J., Ye, X.C., Lee, Y.C., Zurita, A.J., Chen, D.T., Yu-Lee, L.Y., Zhang, S., Yeh, E.T., Hu, M.C.T., et al. (2008). Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol. Cancer Res. 6, 1259-1267. https://doi.org/10.1158/1541-7786.MCR-08-0077
- Cierpicki, T. and Grembecka, J. (2014). Challenges and opportunities in targeting the menin- MLL interaction. Future Med. Chem. 6, 447-462. https://doi.org/10.4155/fmc.13.214
- Dreijerink, K.M.A., Groner, A.C., Vos, E.S.M., Font-Tello, A., Gu, L., Chi, D., Reyes, J., Cook, J., Lim, E., Lin, C.Y., et al. (2017a). Enhancer-mediated oncogenic function of the Menin tumor suppressor in breast cancer. Cell Rep. 18, 2359-2372. https://doi.org/10.1016/j.celrep.2017.02.025
- Dreijerink, K.M.A., Mulder, K.W., Winkler, G.S., Hoppener, J.W.M., Lips, C.J.M., and Timmers, H.T.M. (2006). Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 66, 4929-4935. https://doi.org/10.1158/0008-5472.CAN-05-4461
- Dreijerink, K.M.A., Timmers, H.T.M., and Brown, M. (2017b). Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. Endocr. Relat. Cancer 24, T135-T145.
- Epstein, J.I., Amin, M.B., Beltran, H., Lotan, T.L., Mosquera, J.M., Reuter, V.E., Robinson, B.D., Troncoso, P., and Rubin, M.A. (2014). Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38, 756-767. https://doi.org/10.1097/PAS.0000000000000208
- Feldman, B.J. and Feldman, D. (2001). The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45. https://doi.org/10.1038/35094009
- Feng, Z.J., Ma, J., and Hua, X.X. (2017a). Epigenetic regulation by the menin pathway. Endocr. Relat. Cancer 24, T147-T159. https://doi.org/10.1530/ERC-16-0568
- Feng, Z.J., Wang, L., Sun, Y.M., Jiang, Z.Z., Domsic, J., An, C.Y., Xing, B.W., Tian, J.J., Liu, X.H., Metz, D.C., et al. (2017b). Menin and Daxx interact to suppress neuroendocrine tumors through epigenetic control of the membrane metallo-endopeptidase. Cancer Res. 77, 401-411. https://doi.org/10.1158/0008-5472.CAN-16-1567
- Fujita, H., Okada, F., Hamada, J., Hosokawa, M., Moriuchi, T., Koya, R.C., and Kuzumaki, N. (2001). Gelsolin functions as a metasatsis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int. J. Cancer 93, 773-780. https://doi.org/10.1002/ijc.1413
- Gang, D., Hongwei, H., Hedai, L., Ming, Z., Qian, H., and Zhijun, L. (2013). The tumor suppressor protein menin inhibits NF-kappa B-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma. Mol. Biol. Rep. 40, 2461-2466. https://doi.org/10.1007/s11033-012-2326-0
- Gherardi, S., Ripoche, D., Mikaelian, I., Chanal, M., Teinturier, R., Goehrig, D., Cordier-Bussat, M., Zhang, C.X., Hennino, A., and Bertolino, P. (2017). Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification. Biochim. Biophys. Acta Gene Regul. Mech. 1860, 427-437. https://doi.org/10.1016/j.bbagrm.2017.02.003
- Grembecka, J., He, S.H., Shi, A.B., Purohit, T., Muntean, A.G., Sorenson, R.J., Showalter, H.D., Murai, M.J., Belcher, A.M., Hartley, T., et al. (2012). Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8, 277-284. https://doi.org/10.1038/nchembio.773
- Gururajan, M., Cavassani, K.A., Sievert, M., Duan, P., Lichterman, J., Huang, J.M., Smith, B., You, S.Y., Nandana, S., Chu, G.C.Y., et al. (2015). SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget 6, 44072-44083. https://doi.org/10.18632/oncotarget.6398
- Huang, J., Gurung, B., Wan, B.B., Matkar, S., Veniaminova, N.A., Wan, K., Merchant, J.L., Hua, X.X., and Lei, M. (2012). The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482, 542-546. https://doi.org/10.1038/nature10806
- Huang, S., Chi, Y.Y., Qin, Y., Wang, Z.L., Xiu, B.Q., Su, Y.H., Guo, R., Guo, L., Sun, H.F., Zeng, C.J., et al. (2018). CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription. Theranostics 8, 2549-2564. https://doi.org/10.7150/thno.22523
- Hughes, C.M., Rozenblatt-Rosen, O., Milne, T.A., Copeland, T.D., Levine, S.S., Lee, J.C., Hayes, D.N., Shanmugam, K.S., Bhattacharjee, A., Biondi, C.A., et al. (2004). Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol. Cell 13, 587-597. https://doi.org/10.1016/S1097-2765(04)00081-4
- Imachi, H., Murao, K., Dobashi, H., Bhuyan, M.M., Cao, X.Y., Kontani, K., Niki, S., Murazawa, C., Nakajima, H., Kohno, N., et al. (2010). Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res. Treat. 122, 395-407. https://doi.org/10.1007/s10549-009-0581-0
- Kempinska, K., Malik, B., Borkin, D., Klossowski, S., Shukla, S., Miao, H.Z., Wang, J.Y., Cierpicki, T., and Grembecka, J. (2018). Pharmacologic inhibition of the menin-MLL interaction leads to transcriptional repression of PEG10 and blocks hepatocellular carcinoma. Mol. Cancer Ther. 17, 26-38. https://doi.org/10.1158/1535-7163.MCT-17-0580
- Kim, H., Lee, J.E., Cho, E.J., Liu, J.O., and Youn, H.D. (2003). Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res. 63, 6135-6139.
- Ko, C.J., Huang, C.C., Lin, H.Y., Juan, C.P., Lan, S.W., Shyu, H.Y., Wu, S.R., Hsiao, P.W., Huang, H.P., Shun, C.T., et al. (2015). Androgen-induced TMPRSS2 activates matriptase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth, and metastasis. Cancer Res. 75, 2949-2960. https://doi.org/10.1158/0008-5472.CAN-14-3297
- Kudithipudi, S., Schuhmacher, M.K., Kebede, A.F., and Jeltsch, A. (2017). The SUV39H1 protein lysine methyltransferase methylates chromatin proteins involved in heterochromatin formation and VDJ recombination. ACS Chem. Biol. 12, 958-968. https://doi.org/10.1021/acschembio.6b01076
- Lachner, M., O'Carroll, N., Rea, S., Mechtler, K., and Jenuwein, T. (2001). Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410, 116-120. https://doi.org/10.1038/35065132
- Liang, K.W., Volk, A.G., Haug, J.S., Marshall, S.A., Woodfin, A.R., Bartom, E.T., Gilmore, J.M., Florens, L., Washburn, M.P., Sullivan, K.D., et al. (2017). Therapeutic targeting of MLL degradation pathways in MLL-rearranged leukemia. Cell 168, 59-72.e13. https://doi.org/10.1016/j.cell.2016.12.011
- Lin, C.Y., Jan, Y.J., Kuo, L.K., Wang, B.J., Huo, C., Jiang, S.S., Chen, S.C., Kuo, Y.Y., Chang, C.R., and Chuu, C.P. (2018). Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5. Cancer Sci. 109, 3564-3574. https://doi.org/10.1111/cas.13776
- Livak, K.J. and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408. https://doi.org/10.1006/meth.2001.1262
- Malik, R., Khan, A.P., Asangani, I.A., Cieslik, M., Prensner, J.R., Wang, X.J., Iyer, M.K., Jiang, X., Borkin, D., Escara-Wilke, J., et al. (2015). Targeting the MLL complex in castration-resistant prostate cancer. Nat. Med. 21, 344-352. https://doi.org/10.1038/nm.3830
- Matkar, S., Thiel, A., and Hua, X.X. (2013). Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem. Sci. 38, 394-402. https://doi.org/10.1016/j.tibs.2013.05.005
- Matoso, A., Zhou, Z.X., Hayama, R., Flesken-Nikitin, A., and Nikitin, A.Y. (2008). Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia. Carcinogenesis 29, 620-628. https://doi.org/10.1093/carcin/bgm207
- Milne, T.A., Hughes, C.M., Lloyd, R., Yang, Z.H., Rozenblatt-Rosen, O., Dou, Y.L., Schnepp, R.W., Krankel, C., LiVolsi, V.A., Gibbs, D., et al. (2005). Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 102, 749-754. https://doi.org/10.1073/pnas.0408836102
- Mishra, A., Ayasolla, K., Kumar, V., Lan, X.Q., Vashistha, H., Aslam, R., Hussain, A., Chowdhary, S., Shoshtari, S.M., Paliwal, N., et al. (2018). Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu. Am. J. Physiol. Renal Physiol. 314, F832-F843. https://doi.org/10.1152/ajprenal.00541.2017
- Mohler, J.L., Antonarakis, E.S., Armstrong, A.J., D'Amico, A.V., Davis, B.J., Dorff, T., Eastham, J.A., Enke, C.A., Farrington, T.A., Higano, C.S., et al. (2019). Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 17, 479-505. https://doi.org/10.6004/jnccn.2019.0023
- Mullany, S.A., Moslemi-Kebria, M., Rattan, R., Khurana, A., Clayton, A., Ota, T., Mariani, A., Podratz, K.C., Chien, J., and Shridhar, V. (2011). Expression and functional significance of HtrA1 loss in endometrial cancer. Clin. Cancer Res. 17, 427-436. https://doi.org/10.1158/1078-0432.CCR-09-3069
- Rao, R.C. and Dou, Y.L. (2015). Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat. Rev. Cancer 15, 334-346. https://doi.org/10.1038/nrc3929
- Reis, S.T., Antunes, A.A., Pontes, J., de Sousa-Canavez, J.M., Dall'Oglio, M.F., Piantino, C.B., da Cruz, J.A.S., Morais, D.R., Srougi, M., and Leite, K.R.M. (2012). Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer. Int. Braz. J. Urol. 38, 167-174. https://doi.org/10.1590/S1677-55382012000200004
- Ross, J.S., Kaur, P., Sheehan, C.E., Fisher, H.A.G., Kaufman, R.A., and Kallakury, B.V.S. (2003). Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod. Pathol. 16, 198-205. https://doi.org/10.1097/01.MP.0000056984.62360.6C
- Shin, M.H., He, Y.L., Marrogi, E., Piperdi, S., Ren, L., Khanna, C., Gorlick, R., Liu, C.Y., and Huang, J. (2016). A RUNX2-mediated epigenetic regulation of the survival of p53 defective cancer cells. PLoS Genet. 12, e1005884. https://doi.org/10.1371/journal.pgen.1005884
- Shin, Y.J. and Kim, J.H. (2012). The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS One 7, e30393. https://doi.org/10.1371/journal.pone.0030393
- Slany, R.K. (2009). The molecular biology of mixed lineage leukemia. Haematologica 94, 984-993. https://doi.org/10.3324/haematol.2008.002436
- Thiel, A.T., Blessington, P., Zou, T., Feather, D., Wu, X.J., Yan, J.Z., Zhang, H., Liu, Z.G., Ernst, P., Koretzky, G.A., et al. (2010). MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17, 148-159. https://doi.org/10.1016/j.ccr.2009.12.034
- Thiel, A.T., Feng, Z.J., Pant, D.K., Chodosh, L.A., and Hua, X.X. (2013). The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBP alpha and differentiation in MLL-AF9 leukemia. Haematologica 98, 918-927. https://doi.org/10.3324/haematol.2012.074195
- Weber, F. and Mulligan, L.M. (2017). Happy 20th anniversary MEN1: from positional cloning to gene function restoration. Endocr. Relat. Cancer 24, E7-E11.
- Wu, G.W., Yuan, M.Q., Shen, S.Q., Ma, X.Y., Fang, J.W., Zhu, L.B., Sun, L.C., Liu, Z.J., He, X.P., Huang, D., et al. (2017). Menin enhances c-Myc-mediated transcription to promote cancer progression. Nat. Commun. 8, 15278. https://doi.org/10.1038/ncomms15278
- Wu, Y., Doepner, M., Hojnacki, T., Feng, Z.J., Katona, B.W., He, X., Ma, J., Cao, Y., Busino, L., Zhou, F.X., et al. (2019). Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway. Am. J. Cancer Res. 9, 1682-1694.
- Xiang, Y.Z., Qiu, Q.C., Jiang, M., Jin, R.J., Lehmann, B.D., Strand, D.W., Jovanovic, B., DeGraff, D.J., Zheng, Y., Yousif, D.A., et al. (2013). SPARCL1 suppresses metastasis in prostate cancer. Mol. Oncol. 7, 1019-1030. https://doi.org/10.1016/j.molonc.2013.07.008
- Xu, B., Li, S.H., Zheng, R., Gao, S.B., Ding, L.H., Yin, Z.Y., Lin, X., Feng, Z.J., Zhang, S., Wang, X.M., et al. (2013). Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription. Proc. Natl. Acad. Sci. U. S. A. 110, 17480-17485. https://doi.org/10.1073/pnas.1312022110
- Xu, Y., Yue, L.Y., Wang, Y.L., Xing, J., Chen, Z.F., Shi, Z., Liu, R.F., Liu, Y.C., Luo, X.M., Jiang, H.L., et al. (2016). Discovery of novel inhibitors targeting the menin-mixed lineage leukemia interface using pharmacophore- and docking-based virtual screening. J. Chem. Inf. Model. 56, 1847-1855. https://doi.org/10.1021/acs.jcim.6b00185
- Yang, Y.J., Song, T.Y., Park, J., Lee, J., Lim, J., Jang, H., Kim, Y.N., Yang, J.H., Song, Y., Choi, A., et al. (2013). Menin mediates epigenetic regulation via histone H3 lysine 9 methylation. Cell Death Dis. 4, e583. https://doi.org/10.1038/cddis.2013.98
- Yi, X.Q., Guo, J.F., Guo, J., Sun, S., Yang, P., Wang, J.J., Li, Y., Xie, L.S., Cai, J., and Wang, Z.H. (2017). EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion. Sci. Rep. 7, 3568. https://doi.org/10.1038/s41598-017-03362-z
- Yokoyama, A., Somervaille, T.C.P., Smith, K.S., Rozenblatt-Rosen, O., Meyerson, M., and Cleary, M.L. (2005). The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207-218. https://doi.org/10.1016/j.cell.2005.09.025
- Yokoyama, A., Wang, Z., Wysocka, J., Sanyal, M., Aufiero, D.J., Kitabayashi, I., Herr, W., and Cleary, M.L. (2004). Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol. 24, 5639-5649. https://doi.org/10.1128/MCB.24.13.5639-5649.2004
- Zhang, H., Pan, Y.Z., Cheung, M., Cao, M., Yu, C., Chen, L., Zhan, L., He, Z.W., and Sun, C.Y. (2019). LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway. Cell Death Dis. 10, 230. https://doi.org/10.1038/s41419-019-1320-z